We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock
News

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock
News

Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6,000,000 (assuming no exercise of the over-allotment option), before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. Cancer Genetics has granted the representative of the underwriters a 45-day option to purchase up to 90,000 additional shares of common stock from Cancer Genetics to cover over-allotments, if any. Shares of Cancer Genetics’ common stock are expected to be quoted on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol “CGIX” beginning on April 5, 2013. Investors will be able to find Real Time Level II quotes for “CGIX” on www.otcmarkets.com.

The offering is expected to close on April 10, 2013, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company, Inc. is acting as co-manager for the offering.

Advertisement